SPONSOR
BeOne Medicines
Total Trials
10
Recruiting
10
Phases
Phase 3, Phase 2, Phase 1, Phase 2, Phase 1
Conditions studied: Hepatocellular CarcinomaLiver CancerMantle Cell LymphomaB Cell LymphomaAdvanced Unresectable Gastric AdenocarcinomaEsophageal Squamous Cell CarcinomaAdvanced Gastroesophageal AdenocarcinomaAcute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
BeOne Medicines is a clinical research sponsor with 10 registered studies on ClinicalTrials.gov, of which 10 are actively recruiting participants. Research covers conditions including Hepatocellular Carcinoma, Liver Cancer, Mantle Cell Lymphoma, B Cell Lymphoma.
The trial portfolio spans Phase 3, Phase 2, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — BeOne Medicines
How many clinical trials has BeOne Medicines sponsored?
ClinicalMetric currently tracks 10 clinical trials sponsored by BeOne Medicines, of which 10 are actively recruiting participants. These trials cover conditions including Hepatocellular Carcinoma, Liver Cancer, Mantle Cell Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does BeOne Medicines research focus on?
BeOne Medicines clinical trials span Hepatocellular Carcinoma, Liver Cancer, Mantle Cell Lymphoma, B Cell Lymphoma, Advanced Unresectable Gastric Adenocarcinoma, and additional conditions. The research pipeline includes Phase 3, Phase 2, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a BeOne Medicines clinical trial?
To participate in a BeOne Medicines trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all BeOne Medicines trials with current recruitment status updated daily.
Clinical Trials by BeOne Medicines
NCT07836530 Phase 3
Recruiting
Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
NCT06742996 Phase 3
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Mantle Cell Lymphoma
NCT07554521 Phase 2
Recruiting
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Advanced Unresectable Gastric Adenocarcinoma
NCT04771130 Phase 1, Phase 2
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
Acute Myeloid Leukemia
NCT07181681 Phase 1
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Solid Tumors
NCT06756932 Phase 1
Recruiting
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Hormone-receptor-positive Breast Cancer
NCT07652736
Recruiting
A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
Advanced Non-Small Cell Lung Cancer
NCT07733180 Phase 2
Recruiting
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
Advanced Esophageal Squamous Cell Carcinoma
NCT06120283 Phase 1
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Advanced Solid Tumor
NCT07590102 Phase 1
Recruiting
A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants
Healthy Volunteers
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology